Shandong Jirun Biomedical Technology

Shandong Jirun Biomedical Technology is a Chinese biopharmaceutical company specializing in the research, development, and production of peptide and small molecule drugs. Headquartered in Jinan, the company focuses on metabolic diseases, particularly diabetes and obesity, and has established a strong presence in the GLP-1 receptor agonist market. Jirun Biomedical operates a comprehensive R&D platform that covers the entire drug development lifecycle, from molecular design to GMP-compliant manufacturing. Their portfolio includes high-profile generic biosimilars such as Liraglutide and Semaglutide, alongside innovative therapeutic candidates. The company aims to provide affordable, high-quality treatments for chronic conditions through its integrated chemical and biological synthesis capabilities.